Cumberland Pharmaceuticals (NASDAQ:CPIX) Shares Cross Above Two Hundred Day Moving Average – Here’s Why

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) shares passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $3.96 and traded as high as $5.68. Cumberland Pharmaceuticals shares last traded at $5.67, with a volume of 9,770 shares changing hands.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded shares of Cumberland Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, May 8th.

Cumberland Pharmaceuticals Trading Up 2.9%

The company has a debt-to-equity ratio of 0.41, a current ratio of 1.13 and a quick ratio of 0.99. The business’s 50 day simple moving average is $4.90 and its 200 day simple moving average is $3.96. The company has a market capitalization of $84.83 million, a price-to-earnings ratio of -7.36 and a beta of -0.29.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last released its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $0.15 EPS for the quarter. Cumberland Pharmaceuticals had a negative net margin of 29.54% and a negative return on equity of 9.50%.

Hedge Funds Weigh In On Cumberland Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Berkshire Asset Management LLC PA acquired a new stake in shares of Cumberland Pharmaceuticals in the first quarter worth $692,000. Adage Capital Partners GP L.L.C. bought a new position in Cumberland Pharmaceuticals during the 1st quarter valued at $634,000. Informed Momentum Co LLC bought a new position in shares of Cumberland Pharmaceuticals in the 1st quarter worth about $304,000. Walleye Capital LLC bought a new position in shares of Cumberland Pharmaceuticals in the 1st quarter worth about $298,000. Finally, Two Sigma Investments LP increased its holdings in shares of Cumberland Pharmaceuticals by 94.3% in the 4th quarter. Two Sigma Investments LP now owns 37,649 shares of the specialty pharmaceutical company’s stock worth $89,000 after acquiring an additional 18,271 shares during the period. Institutional investors and hedge funds own 15.51% of the company’s stock.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.